Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Receivables (2018 - 2025)

Ultragenyx Pharmaceutical has reported Change in Receivables over the past 8 years, most recently at $33.8 million for Q4 2025.

  • Quarterly Change in Receivables rose 60.79% to $33.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.0 million through Dec 2025, down 8.82% year-over-year, with the annual reading at $31.0 million for FY2025, 8.82% down from the prior year.
  • Change in Receivables was $33.8 million for Q4 2025 at Ultragenyx Pharmaceutical, up from -$5.4 million in the prior quarter.
  • Over five years, Change in Receivables peaked at $33.8 million in Q4 2025 and troughed at -$10.1 million in Q1 2025.
  • The 5-year median for Change in Receivables is $2.3 million (2021), against an average of $5.3 million.
  • Year-over-year, Change in Receivables tumbled 955.56% in 2022 and then soared 7700.0% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $3.1 million in 2021, then skyrocketed by 196.25% to $9.1 million in 2022, then plummeted by 108.69% to -$790000.0 in 2023, then surged by 2763.54% to $21.0 million in 2024, then skyrocketed by 60.79% to $33.8 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Change in Receivables are $33.8 million (Q4 2025), -$5.4 million (Q3 2025), and $12.7 million (Q2 2025).